Group 1: Intuitive Surgical Overview - Intuitive Surgical is a leader in surgical robotics, primarily due to its da Vinci surgical systems, with 11,106 systems installed by the end of 2025, reflecting a 12% year-over-year increase [2] - The number of surgeries performed using da Vinci systems increased by 18% year-over-year, indicating strong demand for the company's robots [2] - Approximately 25% of Intuitive Surgical's revenue comes from new robot sales, while the majority is generated from parts and services, creating a stable income stream that grows with each new system sold [5] Group 2: Competitive Landscape - Medtronic, a competitor in the medical device sector, has a P/E ratio of 26, making it a more attractively valued option compared to Intuitive Surgical's P/E ratio of 64 [1][6] - Medtronic is developing its own surgical robot, Hugo, which is not as advanced as the da Vinci system but is progressing and presents a significant growth opportunity [6][7] - Medtronic's diversified portfolio as one of the largest medical device companies supports its entry into surgical robotics, and the FDA approved Hugo for use in the U.S. in late 2025 [7] Group 3: Investment Considerations - Medtronic offers a dividend yield of 2.9% and is approaching Dividend King status, with a history of annual dividend increases nearing 50 years [8] - A $10,000 investment in Medtronic could yield around 100 shares, and as the Hugo system's installed base expands over the next decade, the stock may see a higher valuation, providing both income and growth potential [9]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Commission File Number 001-36820 Identification No.) Building Two, Parkmore Business Park West Galway, Ireland (Address of principal executive offices) +353 1 438-1700 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State of incorporation) (I.R.S. Employer | Title of each cla ...

By Arasu Kannagi Basil Feb 24 (Reuters) - Medtronic's MiniMed Group said on Tuesday it was targeting up to $7.86 billion valuation in its U.S. initial public ‌offering, marking a step forward in the medical device maker's plan to ‌separate its diabetes business. The Northridge, California-based unit, a heavyweight in diabetes care and which makes products such ​as insulin pumps, glucose monitoring systems and sensors, is seeking to raise up to $784 million in its IPO by offering 28 million shares priced ...

全球医疗器械巨头美敦力(MDT.US)旗下的糖尿病业务部门MiniMed Group(MMED.US)于当地时间周二 正式迈出独立上市的关键一步。根据该公司向美国证券交易委员会(SEC)提交的最新S-1修订文件显示， MiniMed计划在纳斯达克全球精选市场挂牌上市，股票代码定为"MMED"。此次IPO计划发行2800万股 普通股，每股定价区间设在25美元至28美元之间。若按照定价区间的上限计算，此次首次公开募股的融 资规模将达到7.84亿美元，而该业务部门的整体估值也将提升至约78.6亿美元。 此次IPO标志着美敦力自2024年5月宣布战略调整以来的重要里程碑。作为长期以来全球胰岛素泵市场 的领导者，MiniMed的业务历史可追溯至1983年，并于2001年被美敦力以约33亿美元的价格收归旗下。 随着医疗科技市场的演变，美敦力决定通过分拆糖尿病部门来简化企业架构，以便将核心资源集中于更 高增长、高利润的领域。 来源：智通财经网 在经历了2025年12月的秘密递表后，MiniMed目前的财务状况也随之披露。尽管其在2025财年创造了约 27亿至29亿美元的年收入，且拥有包括MiniMed 780G系统在内的先 ...

此次IPO标志着美敦力自2024年5月宣布战略调整以来的重要里程碑。作为长期以来全球胰岛素泵市场 的领导者，MiniMed的业务历史可追溯至1983年，并于2001年被美敦力以约33亿美元的价格收归旗下。 随着医疗科技市场的演变，美敦力决定通过分拆糖尿病部门来简化企业架构，以便将核心资源集中于更 高增长、高利润的领域。 智通财经APP获悉，全球医疗器械巨头美敦力(MDT.US)旗下的糖尿病业务部门MiniMed Group(MMED.US)于当地时间周二正式迈出独立上市的关键一步。根据该公司向美国证券交易委员会 (SEC)提交的最新S-1修订文件显示，MiniMed计划在纳斯达克全球精选市场挂牌上市，股票代码定 为"MMED"。此次IPO计划发行2800万股普通股，每股定价区间设在25美元至28美元之间。若按照定价 区间的上限计算，此次首次公开募股的融资规模将达到7.84亿美元，而该业务部门的整体估值也将提升 至约78.6亿美元。 在资本结构安排上，美敦力在本次IPO完成后预计将保留MiniMed约90%的股权，若承销商充分行使超 额配售选择权，则持股比例约为89%。面对德康医疗(DXCM.US)和雅培(AB ...

MiniMed announces launch of IPO roadshow [Accessibility Statement] Skip NavigationGALWAY, Ireland, Feb. 24, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed), a subsidiary of Medtronic plc (Medtronic) (NYSE: MDT), today announced that it has launched a roadshow for the initial public offering (IPO) of 28,000,000 shares of its common stock. The proposed offering is part of Medtronic's previously announced plan to separate its Diabetes business into an independent public company.The IPO price is currently ex ...

Group 1 - Medtronic's MiniMed Group is targeting to raise up to $784 million in its initial public offering (IPO) in the United States [1] - The IPO is part of Medtronic's strategy to enhance its diabetes business and expand its market presence [1]

Core Insights - Medtronic plc (NYSE:MDT) is recognized as one of the top 10 healthcare equipment stocks favored by hedge funds [1] - The company operates in four segments: Cardiovascular, Diabetes, Medical-Surgical, and Neuroscience, addressing over 70 chronic diseases [3] Analyst Ratings and Price Targets - Truist analyst Richard Newitter reduced the price target for Medtronic from $107 to $103 while maintaining a Hold rating, citing modest organic revenue and a slight EPS beat [1] - Barclays analyst Matt Miksic maintained an Overweight rating and increased the price target from $116 to $118, indicating a potential upside of nearly 22% [2] Performance Highlights - Medtronic reported solid performance, exceeding street expectations in three out of four segments, with notable strength in the Diabetes and Cardiovascular divisions [1] - The stock's reaction to the earnings beat was moderated by preliminary commentary on potential challenges for fiscal 2027 [2]

Core Insights - The healthcare sector, particularly pharmaceutical and medical device companies, showed strong performance in the 2025 earnings season, outperforming the industry average [1][2] - Key companies discussed include Eli Lilly, AstraZeneca, Edwards Lifesciences, and Medtronic, highlighting significant revenue growth drivers [1] Sector Performance - The earnings reports reflect a backdrop of challenges such as geopolitical shifts, pricing pressures, and patent losses affecting the industry [2]

Core Viewpoint - Medtronic is highlighted as an attractive investment primarily due to its impressive dividend track record, having increased dividends for 48 consecutive years, positioning it to potentially join the ranks of Dividend Kings [1][3]. Dividend Program - The company has a remarkable history of increasing dividends, which is a strong indicator of its reliability and business stability [3][7]. - Achieving 48 years of consecutive dividend increases is a significant accomplishment, suggesting that Medtronic is a steady and reliable business that performs well regardless of economic conditions [4][7]. Financial Performance - Medtronic's revenue growth is consistent, supported by its extensive portfolio in the healthcare industry, although it may not be exceptionally high [6]. - The company has a gross margin of 67.46% and a dividend yield of 2.92%, indicating strong financial health [6]. Business Strategy - Management is divesting from its low-margin diabetes-care business, which is expected to enhance operating margins and profits [8]. - New product launches, such as the Hugo robot-assisted surgery system and pulse-field ablation treatment, are anticipated to drive sales growth in the medium term [9]. Market Position - Medtronic is one of the largest medical device companies globally, with a market capitalization of $124 billion [10]. - The stock is particularly appealing to income-seeking investors rather than those looking for high-growth opportunities [9].